PNS96 LAUNCH DELAY OF HIGH-VALUE DRUGS IN CHINA.

National price negotiations in China manage to improve affordability of drugs of high value in both money and clinic, and we intend to explore the implication of launch delay on their timely accessibility. Launch delay was defined as the gap days between the approval date of either the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) and that of the China Center of Drug Evaluation (CDE), and we determined the launch delay of each indication covered by the medical insurance of every specific drug. The Pearson correlation coefficient of the launch delay of the drugs and their each first launch date in EU or the U.S. was -0.5608 (P<0.0001), indicating the drug lag tended to be attenuated over time. [Extracted from the article]